KK Marine Pharmaceuticals

Tag: Hatch-Waxman Act

Recent Patent Cases and Generic Delays: 2023-2025 Examples
Kimberly Ashworth

Recent Patent Cases and Generic Delays: 2023-2025 Examples

Despite FDA approval, many generic drugs face years of delays due to patent litigation. Between 2023 and 2025, patent thicketing, 30-month stays, and complex drug types pushed average launch delays to 3.2 years, costing patients billions.

8 Jan 2026
What Is an ANDA? Abbreviated New Drug Application Explained
Kimberly Ashworth

What Is an ANDA? Abbreviated New Drug Application Explained

An ANDA is the FDA pathway that allows generic drugs to enter the market without repeating expensive clinical trials. It saves billions annually and ensures safe, effective alternatives to brand-name medications.

27 Nov 2025

Browse by category

  • Health (156)

Latest news

  • Mood Stabilizers: Lithium, Valproate, and Carbamazepine Interactions Explained
  • Pediatric Safety: What Parents and Providers Need to Know About Generic Drugs for Children
  • Fermented Foods and MAOIs: Tyramine Triggers Beyond Cheese
  • How to Use Magnesium Hydroxide for Acid Reflux Relief (Doses, Timing, Safety, NZ 2025)
  • How to Appeal Insurance Denials for Generic Medications: A Step-by-Step Guide

Posts Tags

  • online pharmacy
  • medication safety
  • side effects
  • drug safety
  • pediatric medication safety
  • generic substitution
  • FDA approval
  • statin side effects
  • adverse drug reactions
  • generic medications
  • generic drugs
  • weight loss
  • heart health
  • mental health
  • medicine delivery
  • telehealth
  • Sildenafil
  • ED medication comparison
  • diphenhydramine
  • generic antibiotics
KK Marine Pharmaceuticals
Menu
  • About Us
  • Terms of Service
  • Privacy Policy
  • Data Protection
  • Contact Us

© 2026. All rights reserved.